Full text is available at the source.
Abstract
Once-weekly IcoSema could address glycemic control, weight, and multiple cardiometabolic risk factors with a single injection.
- Patients with type 2 diabetes have a high residual risk of atherosclerotic cardiovascular disease.
- Current therapies may not fully mitigate this risk.
- IcoSema is a combination of two medications: basal insulin icodec and semaglutide.
- The combination therapy is administered once a week.
Simplified